Listen
Reason for request
-
Clinical Benefit
| Low |
Low, and provisional pending re-evaluation of gliptins in triple therapy, in combination with insulin and metformin when this combination alone, with diet and exercise, does not provide adequate glycaemic control. |
| Insufficient |
Insufficient, and provisional pending re-assessment of gliptins in dual therapy, in combination with insulin when this treatment alone, with diet and exercise, does not provide adequate glycaemic control, for reimbursement by national insurance. |
Clinical Added Value
| no clinical added value |
In triple therapy in combination with insulin and metformin, ONGLYZA does not offer any improvement in actual benefit (IAB V, non-existent) in the treatment of patients with type 2 diabetes in whom this combination alone, with diet and exercise, does not provide adequate glycaemic control. |
| Not applicable |
In dual therapy in combination with insulin : not applicable. |
